Novel monoclonal antibody therapy shows promising results in patients with moderate to severe atopic dermatitis

Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab-;a novel, patient-tailored monoclonal antibody therapy-;showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in The Lancet.

source https://www.news-medical.net/news/20221212/Novel-monoclonal-antibody-therapy-shows-promising-results-in-patients-with-moderate-to-severe-atopic-dermatitis.aspx

Comments

Post a Comment

Popular posts from this blog

High levels of memory killer cells correlate with better survival in melanoma patients

Our skin contains specialized long-lived killer cells that protect against intruders. Researchers at Karolinska Institutet in Sweden and the University of Copenhagen in Denmark have now identified how these cells are formed, and shown that high levels of memory killer cells in cancer tissue correlate with a better survival rate in people with melanoma. source https://www.news-medical.net/news/20230602/High-levels-of-memory-killer-cells-correlate-with-better-survival-in-melanoma-patients.aspx
Read more

Sebum RNA could provide reliable biomarkers for detecting early-onset atopic dermatitis

Eczema is an inflammatory skin condition that often affects infants as young as one to two months. Among the various types of eczema seen in infants, early-onset atopic dermatitis (AD), characterized by psychological stress and sleep disorders, is particularly concerning. source https://www.news-medical.net/news/20230608/Sebum-RNA-could-provide-reliable-biomarkers-for-detecting-early-onset-atopic-dermatitis.aspx
Read more